Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases

NCT03271372 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03271372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03271372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
Lead sponsor
University of Washington
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 19, 2017
Completion date
February 18, 2029
Enrollment
101 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii merkel cell carcinoma ajcc v8, stage iiia merkel cell carcinoma ajcc v8, stage iiib merkel cell carcinoma ajcc v8